Incretins are gut-derived peptides released after nutrient intake. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) amplify glucose-dependent insulin secretion and influence appetite and gastric emptying — the biology underlying modern incretin-mimetic research compounds.
Why researchers care
- GLP-1 receptor agonism is the shared mechanism across first-generation metabolic peptides studied for glycaemia and body-weight outcomes.
- GIP receptor activity appears in dual agonists and may alter insulin sensitivity and adipose signalling relative to GLP-1 alone.
- Published trials report large effect sizes — always read primary papers and labels for approved drugs, not catalogue marketing.
TARA supplies research materials. Clinical trial results for approved medicines are educational context, not instructions for laboratory compound use in humans.